Tesamorelin: Drug-Approved GH Analog, Off-Label Use, and Compounding Restrictions

Tesamorelin is the only peptide in this series the FDA actually approved as a drug. It works, in HIV-associated lipodystrophy, the one population it was tested in. The people buying it for longevity don’t have that condition, and the rules that let pharmacies compound BPC-157 don’t apply here at all. That mismatch is the story, so let’s start there.

What tesamorelin is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), with a trans-3-hexenoic acid group attached that makes it last longer in plasma than native GHRH. It binds and activates the GHRH receptor on pituitary somatotrophs, releasing GH through the same pathway your own GHRH uses. The longer half-life is what makes once-daily subcutaneous dosing workable.

It was built for one job: the visceral abdominal fat that builds up in HIV patients on certain antiretroviral drugs, a well-documented side effect called lipodystrophy. A defined patient group, a hard endpoint (visceral adipose tissue on CT), and a real unmet need is exactly the setup a drug approval needs, and tesamorelin got one.

The trials behind the approval

The clinical evidence for tesamorelin in its approved indication is among the strongest for any peptide in this class.

The pivotal Phase III trial ran in the New England Journal of Medicine in 2007. Falutz and colleagues randomised 412 HIV-infected adults with excess abdominal fat to the study-dose tesamorelin or placebo, given by daily subcutaneous injection for 26 weeks. Visceral adipose tissue on CT fell 15.2% on tesamorelin and rose 5% on placebo. Triglycerides dropped, the total/HDL cholesterol ratio improved, IGF-I rose 81%. This is human data, in a real trial, with a placebo arm. That’s not a sentence you get to write about most peptides.

Post-approval, the research moved into non-HIV groups. A 12-month randomised trial in the Journal of Clinical Endocrinology and Metabolism by Makimura and colleagues enrolled 60 abdominally obese adults without HIV who had reduced endogenous GH secretion. Tesamorelin selectively reduced visceral fat, dropped triglycerides and C-reactive protein, and even nudged carotid intima-media thickness in the right direction. Glycaemic control didn’t worsen. The trial is small and single-centre, but it is an actual placebo-controlled RCT outside the HIV indication.

Approved, off-label, compounded — three different lanes

Tesamorelin needs the approved-versus-off-label line drawn carefully.

The approved indication: tesamorelin (Egrifta, marketed by Theratechnologies) received FDA drug approval in November 2010 under NDA 022505, for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The approval rests on demonstrated efficacy and safety in that population. The product line has evolved through three formulations — Egrifta (F1, 2010), Egrifta SV (F4 reformulation, 2019), and the current Egrifta WR (F8 formulation, approved March 25, 2025 via supplemental BLA, replacing SV). Egrifta WR is a daily injectable with weekly reconstitution rather than SV’s daily reconstitution; pharmacokinetic studies showed bioequivalence to the original F1 tesamorelin.

Off-label use: the longevity and performance interest is mostly off-label, visceral fat reduction and metabolic improvement in non-HIV people. A licensed physician prescribing an approved drug off-label is legal in the US. It’s still a different thing from the approved indication, and it isn’t backed by the same controlled evidence.

Compounding restrictions: this is the part that actually matters. Because tesamorelin is the active moiety of a commercially available, drug-approved product (Egrifta), the FD&C Act bars compounding pharmacies from compounding substances that are essentially copies of approved drugs. That’s the opposite of BPC-157 or TB-500, which have no approved form to copy. Compounded tesamorelin has drawn FDA enforcement and ongoing legal analysis.

Tesamorelin isn’t on the PCAC July 23–24, 2026 docket. It runs under the drug approval framework, not the bulk substances compounding pathway — PCAC reviews unapproved bulk substances, and tesamorelin has an approved form to copy.

WADA’s 2026 Prohibited List S2 category — Growth Hormone Releasing Factors and their analogs — covers tesamorelin. If you compete, treat it as prohibited, in and out of competition.

What’s still uncharacterised

This is the honest part, so read it twice.

Long-term outcomes in non-HIV people aren’t well-characterised by controlled studies. The Makimura 12-month trial moved the needle on surrogate markers; whether those translate into real cardiovascular events or metabolic benefit in non-HIV older adults isn’t established by long-term outcome data.

Sustained tesamorelin-driven GH elevation interacting with IGF-1 pathways over years hasn’t been characterised in the longevity context. The GHRH-GH-IGF-1 axis has tangled effects on cell proliferation and metabolic regulation, and those want long-term study.

And the regulatory environment for compounded tesamorelin is genuinely uncertain. Practitioners and patients in this space face legal complexity that doesn’t exist for research-stage compounds with no approved form.

Where tesamorelin lands

Tesamorelin is the best-evidenced GH-axis peptide here for its approved use. The Phase III trial is rigorous and the visceral fat effect in HIV lipodystrophy is well-established. The distance from that approved indication to the off-label longevity use driving most of the interest is wide, in both the evidence and the law.

The honest framing, if you’re tracking this: the drug works for what it was approved for, the off-label case rests on thinner data, and the compounding restriction makes the prescription pathway genuinely complicated in a way the research peptides aren’t. Approved doesn’t mean approved for the thing people want it for.